Literature DB >> 19329222

XRCC1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis.

Huilie Zheng1, Zhongxu Wang, Xiuquan Shi, Zengzhen Wang.   

Abstract

X-ray repair cross-complementing group 1 (XRCC1), one of the >20 genes that participate in the base excision repair (BER) pathway, is thought to account for differences in lung cancer susceptibility. Our meta-analysis on 2861 cases (lung cancer patients) and 2783 controls from eight eligible studies in Chinese populations showed that for the XRCC1 Arg194Trp polymorphism, compared with the Arg/Arg homozygous genotype, the variant Arg/Trp and Trp/Trp genotypes combined was not associated with lung cancer risk (OR=1.06, 95% confidence interval [CI]=0.89-1.27) (Z=0.70, P=0.48), nor was Arg280His (OR=0.63, 95% CI=0.28-1.41) (Z=1.12, P=0.26); however, for the XRCC1 Arg399Gln polymorphism, the combination of variant Arg/Gln and Gln/Gln genotypes was borderline significantly associated with lung cancer risk (OR=1.16, 95% CI=1.00-1.36) (Z=1.90, P=0.06), compared with the Arg/Arg homozygous genotype. Therefore, in the eight published studies in Chinese populations, we found little evidence of an association between the combined variant genotypes of the XRCC1Arg399Gln polymorphism and the increased risk of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19329222     DOI: 10.1016/j.lungcan.2009.02.002

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  18 in total

1.  XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 case-control studies.

Authors:  Liping Dai; Fujiao Duan; Peng Wang; Chunhua Song; Kaijuan Wang; Jianying Zhang
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

2.  Note of clarification of data in the paper titled X-ray repair cross-complementing group 1 codon 399 polymorphism and lung cancer risk: an updated meta-analysis.

Authors:  Wenlong Zhai; Ruo Feng; Haiyu Wang; Yadong Wang
Journal:  Tumour Biol       Date:  2015-04-03

3.  The Arg194Trp polymorphism in the XRCC1 gene and cancer risk in Chinese Mainland population: a meta-analysis.

Authors:  Jin Huang; Jie Zhang; Yuliang Zhao; Banghua Liao; Jiaming Liu; Ling Li; Mingheng Liao; Lanlan Wang
Journal:  Mol Biol Rep       Date:  2011-04-16       Impact factor: 2.316

4.  Genetic polymorphisms of DNA repair gene XRCC1 and risk of uterine leiomyoma.

Authors:  Yang Yang; Xian Dun Zhai; Lin Bo Gao; Shi Liu Li; Zheng Wang; Guo Di Chen
Journal:  Mol Cell Biochem       Date:  2009-12-15       Impact factor: 3.396

5.  XRCC1 genetic polymorphism acts a potential biomarker for lung cancer.

Authors:  Dao-Qi Zhu; Qiong Zou; Chun-Hong Hu; Jia-Li Su; Guang-Hua Zhou; Ping Liu
Journal:  Tumour Biol       Date:  2015-01-08

6.  Genetic polymorphisms in key DNA repair genes and risk of head and neck cancer in a Chinese population.

Authors:  Hua Yuan; Huizhang Li; Hongxia Ma; Yuming Niu; Yunong Wu; Shangyue Zhang; Zhibin Hu; Hongbing Shen; Ning Chen
Journal:  Exp Ther Med       Date:  2012-02-09       Impact factor: 2.447

7.  DNA repair genes polymorphism and lung cancer risk with the emphasis to sex differences.

Authors:  L Letkova; T Matakova; L Musak; M Sarlinova; M Krutakova; P Slovakova; E Kavcova; V Jakusova; M Janickova; A Drgova; P Berzinec; E Halasova
Journal:  Mol Biol Rep       Date:  2013-05-15       Impact factor: 2.316

8.  XRCC1 polymorphisms and lung cancer risk in Caucasian populations: a meta-analysis.

Authors:  Liangdong Chen; Deqiang Zhuo; Jiakuan Chen; Hongyin Yuan
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 9.  Genetic susceptibility to lung cancer--light at the end of the tunnel?

Authors:  Ariela L Marshall; David C Christiani
Journal:  Carcinogenesis       Date:  2013-01-24       Impact factor: 4.944

Review 10.  X-ray repair cross-complementing group 1 polymorphisms and hepatocellular carcinoma: a meta-analysis.

Authors:  Tian Xie; Zhen-Guang Wang; Jing-Lei Zhang; Hui Liu
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.